Search
Gepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.
Categories: Triazaacenaphthylene Bacterial Type II Topoisomerase InhibitorComplement C5
go.drugbank.com/bio_entities/BE0000855TargetHumansPrecursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that … Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279)
Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.
Categories: Enzymes and Coenzymes, Alimentary Tract and MetabolismLumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia.
Lonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigational[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an … for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.
Categories: Alimentary Tract and Metabolism, Various Alimentary Tract and Metabolism ProductsCupric Chloride
go.drugbank.com/drugs/DB09131ApprovedCupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Synonyms: copper(II) chlorideMixtures: Tracel Injektionslösung in einer Fertigspritze, Trace Elements Solution InjSulconazole
go.drugbank.com/drugs/DB06820ApprovedSulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis … [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial fungal infections.[A255612]
Categories: Imidazole and Triazole DerivativesPolycarbophil
go.drugbank.com/drugs/DB09311ApprovedWithdrawnLess gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. … is physiologically inert, and does not cause gastrointestinal irritation.
Categories: Compounds used in a research, industrial, or household settingSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Categories: MATE 2-K InhibitorsDeep partial-thickness thermal burn
go.drugbank.com/conditions/DBCOND0106398